# US 2011/0034396 A1 · Methods and compositions for inhibiting cell migration and treatment of inflammatory conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0034396 A1
- Document ID: US20110034396A1
- Status: Published application
- Kind: A1
- Application number: 12/807,120
- Filed: 2010-08-27
- Published: 2011-02-10
- Earliest claimed: 2005-09-28
- Assignees: BioVascular, Inc.
- Inventors: Paul F. Glidden
- Web page: https://patentgrep.com/patent/US20110034396A1

## CPC

- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61L 2300/252: Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L 2300/42: Anti-thrombotic agents, anticoagulants, anti-platelet agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides methods of use of saratin, including the prevention or mitigation of the development of adhesions, keloids and scars. The adhesions, keloids and scars can be due to surgery, such as plastic surgery or orthopedic surgery, or can be pre-existing scars. Adhesion, keloid and/or scar formation may also be prevented in surgical procedures utilizing shunts, implants or drainage devices, including surgical procedures to treat glaucoma.

## Claims

### Claim 1

A method of inhibiting white blood cell migration and/or white blood cell adhesion to extracellular matrix proteins in a patient in need thereof comprising administering to the patient an effective amount of saratin.

### Claim 2 (depends on 1)

The method of claim 1, wherein the patient is undergoing a surgical procedure to decrease pressure or drain fluids from a body cavity, space or organ.

### Claim 3 (depends on 2)

The method of claim 2, wherein the surgical procedure is the insertion or creation of a surgical drain.

### Claim 4 (depends on 3)

The method of claim 3, wherein the surgical drain is a trabulectomy, a chest drain, a sinus drain, an otic drain or a cerebrospinal fluid drain.

### Claim 5 (depends on 3)

The method of claim 3, wherein saratin prevents capsule formation at the site of the surgical drain.

### Claim 6 (depends on 2)

The method of claim 2, wherein the surgical procedure is glaucoma surgery.

### Claim 7 (depends on 6)

The method of claim 6, wherein the glaucoma surgery is glaucoma filtering surgery.

### Claim 8 (depends on 1)

The method of claim 1, wherein saratin is administered topically or injected.

### Claim 9 (depends on 1)

The method of claim 1, wherein saratin is administered continually or intermittently.

### Claim 10 (depends on 1)

The method of claim 1, wherein saratin is administered for at least seven days.

### Claim 11 (depends on 1)

The method of claim 1, wherein saratin is administered for at least one month.

### Claim 12 (depends on 1)

The method of claim 1, wherein saratin is administered for at least six months.

### Claim 13 (depends on 1)

The method of claim 1, wherein saratin is administered every third day, every other day or daily.

### Claim 14

A method of treating a white blood cell mediated inflammatory condition comprising administering to a patient in need thereof an effective amount of saratin.

### Claim 15 (depends on 14)

The method of claim 14, wherein the inflammatory condition occurs as a result of a surgical procedure to decrease pressure or drain fluids from a body cavity, space or organ.

### Claim 16 (depends on 15)

The method of claim 15, wherein the surgical procedure is the insertion or creation of a surgical drain.

### Claim 17 (depends on 16)

The method of claim 16, wherein the surgical drain is a trabulectomy, a chest drain, a sinus drain, an otic drain or a cerebrospinal fluid drain.

### Claim 18 (depends on 16)

The method of claim 16, wherein saratin prevents capsule formation at the site of the surgical drain.

### Claim 19 (depends on 15)

The method of claim 15, wherein the surgical procedure is glaucoma surgery.

### Claim 20 (depends on 19)

The method of claim 19, wherein the glaucoma surgery is glaucoma filtering surgery.

### Claim 21 (depends on 14)

The method of claim 14, wherein saratin is administered topically or injected.

### Claim 22 (depends on 14)

The method of claim 14, wherein said treating comprises white blood cell adhesion or white blood cell migration.

### Claim 23 (depends on 22)

The method of claim 22, wherein said white blood cells are lymphocytes, macrophages, monocytes or polymorphonuclear leukocytes.

### Claim 24

A method of treating a surgically-induced complication comprising administering to a patient in need thereof an effective amount of saratin.

### Claim 25 (depends on 24)

The method of claim 24, wherein said surgically-induced complication is surgically-induced inflammation.

### Claim 26 (depends on 24)

The method of claim 24, wherein said surgically-induced complication occurs as a result of a surgical procedure to decrease pressure or drain fluids from a body cavity, space or organ.

### Claim 27 (depends on 26)

The method of claim 26, wherein said surgical procedure is glaucoma surgery, orthopedic surgery, plastic surgery or transplant surgery.

### Claim 28 (depends on 27)

The method of claims 27, wherein said glaucoma surgery is glaucoma filtering surgery.
